ArticleRadiation oncology (London, England)2025
Correlations of biochemical and clinical outcomes with 10-year results after robotic stereotactic body radiotherapy for localized prostate cancer.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong-term data on the efficacy of robotic stereotactic body radiotherapy (SBRT) for localized prostate cancer (LPC) remain limited. This study aimed to evaluate the 10-year treatment outcomes of SBRT in LPC patients and identify key prognostic factors.
methodsA total of 82 patients with LPC who underwent five-fraction SBRT (doses of 35-37.5 Gy) were included. The median follow-up duration was 11.0 years (range, 3.3-15.9 years). Clinical outcomes, including the biochemical failure-free survival (BCFFS), clinical failure-free survival (CFFS), and prostate-specific antigen (PSA) kinetics, were analyzed to evaluate the impact of various clinical and treatment factors on prognosis.
resultsThe 10-year BCFFS and CFFS rates were 86.3% (95% confidence interval [CI], 78.6-94.8) and 86.7% (95% CI, 78.8-95.4), respectively. Nine cases of biochemical failure were observed, alongside local (n = 1), regional (n = 2), and distant (n = 5) metastases. The cancer-specific survival rate was 100%. The median PSA nadir was 0.09 ng/ml (range, 0.0-3.12 ng/ml) and the median interval to PSA nadir was 52.8 months (range, 0.4-170.2 months). There was a negative correlation between the time to the PSA nadir and the PSA nadir value (r = -0.233, p = 0.035). Daily SBRT was associated with improved BCFFS compared to every-other-day treatment (hazard ratio [HR], 0.220; 95% CI, 0.067-0.720; p = 0.012), while a longer interval to PSA nadir (≥ 5 years) was associated with better CFFS (HR, 0.120; 95% CI, 0.015-0.944; p = 0.044).
conclusionsRobotic SBRT for LPC demonstrates durable long-term efficacy. Daily treatment schedules and interval to PSA nadir were identified as crucial prognostic indicators. These findings highlight the importance of PSA kinetics in predicting treatment success following robotic SBRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.